FDA Revenue and Competitors

Location

N/A

Total Funding

Government

Industry

Estimated Revenue & Valuation

  • FDA's estimated annual revenue is currently $15M per year.(i)
  • FDA's estimated revenue per employee is $805

Employee Data

  • FDA has 18635 Employees.(i)
  • FDA grew their employee count by -10% last year.

FDA's People

NameTitleEmail/Phone
1
Associate Chief Counsel for FoodsReveal Email/Phone
2
CSOReveal Email/Phone
3
CSOReveal Email/Phone
4
Chief, Cosmetics Regulatory Activities BranchReveal Email/Phone
5
Chief Mathematical Statistician, FDA Center for Tobacco ProductsReveal Email/Phone
6
Chief, Laboratory Immunology, Office Biotechnology ProductsReveal Email/Phone
7
CSOReveal Email/Phone
8
Acting Branch Chief, Systems Lead, Power BI DeveloperReveal Email/Phone
9
Acting Strategic Communications Branch ChiefReveal Email/Phone
10
Chief Technology OfficerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$3.5M212785%N/AN/A
Add Company

What Is FDA?

The U S. Food and Drug Administration is a scientific, regulatory, and public health agency that oversees items accounting for 25 cents of every dollar spent by consumers. Its jurisdiction encompasses most food products (other than meat and poultry), human and animal drugs, therapeutic agents of biological origin, medical devices, radiation-emitting products for consumer, medical, and occupational use, cosmetics, and animal feed. The agency grew from a single chemist in the U.S. Department of Agriculture in 1862 to a staff of approximately 9,100 employees and a budget of $1.294 billion in 2001, comprising chemists, pharmacologists, physicians, microbiologists, veterinarians, pharmacists, lawyers, and many others. About one-third of the agency's employees are stationed outside of the Washington, D. C. area, staffing over 150 field offices and laboratories, including five regional offices and 20 district offices. Agency scientists evaluate applications for new human drugs and biologics, complex medical devices, food and color additives, infant formulas, and animal drugs. Also, the FDA monitors the manufacture, import, transport, storage, and sale of about $1 trillion worth of products annually at a cost to taxpayers of about $3 per person. Investigators and inspectors visit more than 16,000 facilities a year, and arrange with state governments to help increase the number of facilities checked.

keywords:N/A

N/A

Total Funding

18635

Number of Employees

$15M

Revenue (est)

-10%

Employee Growth %

N/A

Valuation

N/A

Accelerator

FDA News

2022-04-20 - Gottlieb expects FDA to start considering child vaccines in early June

Dr. Scott Gottlieb says he expects the FDA's advisory committee to begin consideration of Moderna's two-dose vaccine for young children in early June,...

2022-04-19 - The FDA Approved a New Drug To Treat Alzheimer’s, but Medicare Won’t Always Pay for It – A Doctor Explains Biogen’s Aduhelm

On April 8, 2022, Medicare finalized its decision to restrict its coverage of Aduhelm, Biogen's new Alzheimer's disease treatment.

2022-04-17 - CDC, FDA, NIH workers did not report incidents of political interference, 'fearing retaliation,' government watchdog agency says

Just because incidents of political interference within the United States' top health agencies are not reported, does not mean they don't...

2021-11-23 - Isofol Medical AB (publ) receives FDA Fast Track Designation for arfolitixorin in advanced colorectal cancer (mCRC)

Isofol Medical AB (publ) receives FDA Fast Track Designation for arfolitixorin in advanced colorectal cancer (mCRC) Tue, Nov 23, 2021 18:45 CET GOTHENBURG, Sweden, November 23, 2021 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), announced today that the U.S. Food and Drug Administration ...

2021-11-19 - BioMarin Receives FDA Approval for VOXZOGO™ (vosoritide) for Injection, Indicated to Increase Linear Growth in Children with Achondroplasia Aged 5 and Up with Open Growth Plates

SAN RAFAEL, Calif., Nov. 19, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to VOXZOGO™ (vosoritide) for Injection, indicated to increase linear growth in pediatric patients with a ...